Group items tagged

Measuring 25-hydroxyvitamin D in a clinical environment: challenges and needs. Hollis BW. Am J Clin Nutr. 2008 Aug;88(2):507S-510S. Review. PMID: 18689391 In this article, I provide an overview of the techniques available for measuring 25(OH)D, compare these techniques with one another, and assess their clinical utility. I also briefly discuss the stability of 25(OH)D in biological media and present an overview of the Vitamin D External Quality Assessment Scheme.

(VIDEO) Shedding light on the vitamin D deficiency 'crisis' By GrassRootsHealth.com Oct 11, 2009 - 4:49:39 PM San Diego, CA - Can vitamin D prevent 80% of the incidence of breast cancer? What is its affect on colon cancer and other major illnesses? These questions and more will be addressed when some of the most prominent vitamin D researchers in North America participate in the " Diagnosis & Treatment of Vitamin D Deficiency" seminar presented by GrassrootsHealth at the University of Toronto on Tuesday, November 3 from 8 a.m. - 5 p.m. GrassrootsHealth is the founder of D*action, an international public health project whose goal is to solve the vitamin D deficiency epidemic. GrassrootsHealth and D*action work with over 30 scientists, institutions and individuals committed to educate, test, and study vitamin D levels worldwide. At the conference, a group of physicians and researchers in the vitamin D field will discuss vitamin D's role in the potential prevention of many diseases, including breast cancer, colon cancer, type 1 diabetes and multiple sclerosis, the ultimate reduction in the incidence of infectious diseases and the economic impact of such action

Safety of vitamin D3 in adults with multiple sclerosis. Kimball SM, Ursell MR, O'Connor P, Vieth R. Am J Clin Nutr. 2007 Sep;86(3):645-51. PMID: 17823429 Conclusions: Patients' serum 25(OH)D concentrations reached twice the top of the physiologic range without eliciting hypercalcemia or hypercalciuria. The data support the feasibility of pharmacologic doses of vitamin D3 for clinical research, and they provide objective evidence that vitamin D intake beyond the current upper limit is safe by a large margin.

D-vitamiinin turvallisuutta tarkasteltaessa pitää huomioida ainakin seuraavat kaksi asiaa: 1) Nykyiset saantisuositukset ja turvallisuurajat ovat aivan liian pieniä, kts. Viethin tutkimukset ja esim. Merckin manuaalista "Vitamin D toxicity". 2) On olemassa näyttöä siitä, että nykyisenkaltaisten suositusten seuraaminen voi altistaa tietyille kroonisille taudeille monia yksilöitä, joiden auringonvalon saanti on syystä tai toisesta rajoitettu (talvisaika 40 leveyasteiden ulkopuolella, liian peittävä vaatetus (musliminaiset) jne..). Tällaisia tauteja ovat mm. tyypin 1 diabetes, multippeli skleroosi ja muut autoimmuunisairaudet, monet syövät (eturauhassyövästä on aika hyvää näyttöä), reuma, osteoporoosi, korkea verenpaine, kaamosmasennus, jne .... Jättiannokset ovat myrkyllisiä, mutta liian vähäinen saantikin voi olla huomattava turvallisuusriski.